For the past 20 years, my laboratory has been at the forefront of applying genome-scale technologies (next-generation sequencing, mRNA profiling and proteomics) and systems approaches to increase our understanding of the molecular mechanisms underlying transcription in Leishmania and other trypanosomatid parasites, as well as regulation of gene expression during differentiation. I am also PI and director of the Seattle Structural Genomics Center for Infectious Disease (SSGCID), which is funded under a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with the mission using X-ray crystallography, NMR spectroscopy and cryo-electron microscopy to solve the structure of proteins from emerging and re-emerging infectious disease organisms (bacteria, viruses and eukaryotic parasites). This data is made freely available to the scientific community in order to understand molecular function of these targets and to facilitate development of new therapeutics by using structure-guided drug and vaccine design.